scholarly journals Identification of a Blood-Based Protein Biomarker Panel for Lung Cancer Detection

Cancers ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 1629 ◽  
Author(s):  
Victoria El-Khoury ◽  
Anna Schritz ◽  
Sang-Yoon Kim ◽  
Antoine Lesur ◽  
Katriina Sertamo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Predictive Value ◽  
Characteristic Curve ◽  
Lung Cancer Screening ◽  
Disease Stage ◽  
Validation Dataset ◽  
Average Risk ◽  
Bootstrap Sampling ◽  
Lung Cancer Patients ◽  
Performance Area

Lung cancer is the deadliest cancer worldwide, mainly due to its advanced stage at the time of diagnosis. A non-invasive method for its early detection remains mandatory to improve patients’ survival. Plasma levels of 351 proteins were quantified by Liquid Chromatography-Parallel Reaction Monitoring (LC-PRM)-based mass spectrometry in 128 lung cancer patients and 93 healthy donors. Bootstrap sampling and least absolute shrinkage and selection operator (LASSO) penalization were used to find the best protein combination for outcome prediction. The PanelomiX platform was used to select the optimal biomarker thresholds. The panel was validated in 48 patients and 49 healthy volunteers. A 6-protein panel clearly distinguished lung cancer from healthy individuals. The panel displayed excellent performance: area under the receiver operating characteristic curve (AUC) = 0.999, positive predictive value (PPV) = 0.992, negative predictive value (NPV) = 0.989, specificity = 0.989 and sensitivity = 0.992. The panel detected lung cancer independently of the disease stage. The 6-protein panel and other sub-combinations displayed excellent results in the validation dataset. In conclusion, we identified a blood-based 6-protein panel as a diagnostic tool in lung cancer. Used as a routine test for high- and average-risk individuals, it may complement currently adopted techniques in lung cancer screening.

scholarly journals Surgically treated lung cancer patients: do they all smoke and would they all have been detected with lung cancer screening?

2018 ◽  
Vol 4 (3) ◽  
pp. 00001-2018 ◽  
Author(s):  
Tanel Laisaar ◽  
Bruno Sarana ◽  
Indrek Benno ◽  
Kaja-Triin Laisaar
Keyword(s):  
Lung Cancer ◽  
Cancer Screening ◽  
Cancer Patients ◽  
Lung Cancer Screening ◽  
University Hospital ◽  
Smoking History ◽  
Inclusion Criteria ◽  
Lung Cancer Patients ◽  
Cancer Screening Trial ◽  
Lung Cancer Detection

Since publication of the National Lung Cancer Screening Trial (NLST) results early lung cancer detection has been widely studied, targeting individuals based on smoking history and age. However, over recent decades several changes in lung cancer epidemiology, including risk factors, have taken place. The aim of the current study was to explore smoking prevalence among lung cancer patients who had been treated surgically or undergone a diagnostic operation and whether these patients would have met the NLST inclusion criteria.All patients operated on for lung cancer in a university hospital in Estonia between 2009 and 2015 were included. Data were collected from hospital records.426 patients were operated on for lung cancer, with smoking history properly documented in 327 patients (87 females; median age 67 years). 170 (52%) patients were smokers, 97 (30%) patients were ex-smokers and 60 (18%) patients were nonsmokers. The proportion of females among smokers was 15%, among ex-smokers was 9% and among nonsmokers was 87%. 107 of our patients would not have met the NLST age criteria and 128 of our patients would not have met the NLST smoking criteria. In total, 183 patients (56% (79% of females and 48% of males)) would not have met the NLST inclusion criteria.Only half of surgically treated lung cancer patients were current smokers and more than half did not meet the NLST inclusion criteria.

Characteristics and Predictive Value of PD-L1 Status in Real-World Non–Small Cell Lung Cancer Patients

2018 ◽  
Vol 41 (6) ◽  
pp. 292-299 ◽  
Author(s):  
Jeng-Sen Tseng ◽  
Tsung-Ying Yang ◽  
Chih-Ying Wu ◽  
Wen-Hui Ku ◽  
Kun-Chieh Chen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Real World ◽  
Predictive Value ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients

Prognostic and predictive value of loss of nuclear RAD51 immunoreactivity in resected non-small cell lung cancer patients

Lung Cancer ◽  
2017 ◽  
Vol 105 ◽  
pp. 31-38 ◽  
Author(s):  
Mariam Gachechiladze ◽  
Josef Škarda ◽  
Vítězslav Kolek ◽  
Ivona Grygárková ◽  
Kateřina Langová ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Predictive Value ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients

scholarly journals DNA Repair Gene Polymorphisms in Relation to Non-Small Cell Lung Cancer Survival

2015 ◽  
Vol 36 (4) ◽  
pp. 1419-1429 ◽  
Author(s):  
Yuliang Su ◽  
Huan Zhang ◽  
Fangxiu Xu ◽  
Jinyu Kong ◽  
Herbert Yu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Dna Repair ◽  
Cancer Survival ◽  
Disease Stage ◽  
Repair Gene ◽  
Lung Cancer Patients ◽  
Homozygous Variant ◽  
Dna Repair Gene ◽  
Nsclc Patients ◽  
Repair Genes

Background: Single nucleotide polymorphisms (SNPs) in the DNA repair genes are suspected to be related to the survival of lung cancer patients due to their possible influence on DNA repair capacity (DRC). However, the study results are inconsistent. Methods: A follow-up study of 610 non-small cell lung cancer (NSCLC) patients was conducted to investigate genetic polymorphisms associated with the DNA repair genes in relation to NSCLC survival; 6 SNPs were genotyped, including XRCC1 (rs25487 G>A), hOGG1 (rs1052133 C>G), MUTYH (rs3219489 G>C), XPA (rs1800975 G>A), ERCC2 (rs1799793 G>A) and XRCC3 (rs861539 C>T). Kaplan-Meier survival curve and Cox proportional hazards regression analyses were performed. SNP-SNP interaction was also examined using the survival tree analysis. Results: Advanced disease stage and older age at diagnosis were associated with poor prognosis of NSCLC. Patients with the variant ‘G' allele of hOGG1 rs1052133 had poor overall survival compared with those with the homozygous wild ‘CC' genotype, especially in female patients, adenocarcinoma histology, early stage, light smokers and without family history of cancer. For never smoking female lung cancer patients, individuals carrying homozygous variant ‘AA' genotype of XPA had shorter survival time compared to those with wild ‘G' alleles. Furthermore, females carrying homozygous variant XPA and hOGG1 genotypes simultaneously had 2.78-fold increased risk for death. Among all 6 polymorphisms, the homozygous variant ‘AA' of XPA carriers had poor prognosis compared to the carriers of wild ‘G' alleles of XPA together with other base excision repair (BER) polymorphisms. Conclusions: Besides disease stage and age, the study found DNA repair gene polymorphisms were associated with lung cancer survival.

scholarly journals PROSPECTS FOR THE APPLICATION OF THE MOST MODERN METHODS OF DIAGNOSIS OF LUNG CANCER

2019 ◽  
pp. 3-7
Author(s):  
I. О. Vynnychenko ◽  
Yu. V. Moskalenko ◽  
O. І. Vynnychenko ◽  
M. Yu. Serdyuk ◽  
O. А. Ternovenko
Keyword(s):  
Lung Cancer ◽  
Lung Cancer Screening ◽  
Human Lung Cancer ◽  
Endobronchial Ultrasound ◽  
Lung Cancer Patients ◽  
Current State ◽  
Modern Methods ◽  
Screening Sensitivity ◽  
Diagnosis Of Lung Cancer

Lung cancer is one of the major causes of death from malignancies. That is why the article devoted to the issue early diagnosis of lung cancer. The objective of the work is to consider the features and prospects of using the most modern methods of diagnosis of lung cancer. The introduction of the latest technologies is essential for quality screening of lung cancer patients. Gradually, there is a growing interest in developing strategies around the world to better assess the risk of human lung cancer, increase screening sensitivity, and reduce costs. The methods of early detection of lung cancer are described in the article: determination of the concentration of volatile organic compounds (LuCID method), endobronchial ultrasound (EBUS method), FISH-marker method, basic principles of the Nano-Nose device. Despite some advances in our country in the diagnosis of lung cancer using common advanced methods of computed tomography and biopsy, the introduction of foreign experience in lung cancer screening is necessary, because the current state-of-the-art methods of diagnosis allow to detect cancer.

Sign in / Sign up

Export Citation Format

Share Document